Real World Data Capabilities: Benchmarking pharma companies
Is Real World Data giving your market access the power charge it needs?
Real World Data (RWD) and Real World Evidence (RWE) are gaining traction across the industry. The front runners are already exploring new ways to collect and use data within their market access strategies and, for some, this is proving an effective way to ‘tip the balance’ from a no to a yes with target agencies. How well is pharma leveraging the data advantage? And how should companies benchmark their own RWD activities against the best of the rest?
Report Overview
Seven senior pharmaceutical company decision-makers currently working in Real World Data and Real World Evidence were all interviewed in depth. RWD Benchmarking Capabilities details their perspectives on the use of RWD and RWE for market access now and in the future, including opinions on who is leading the field and why.
Report Features
At the heart of the Real World Data revolution is the issue of control. Pharma companies used to be in the driving seat when it came to the data produced from trials and studies of their drugs. But now the floodgates have opened and everyone from payers to patients to your competitors can all see and comment on real world drug performance. And they are, in droves. This new data-rich environment presents significant opportunities but also threats. The key to success is finding a strategy that is sustainable, meets commercial objectives, and produces insight that is ultimately trusted enough to influence opinion.
Key Questions Answered By This Report
Each of our experts have detailed understanding of RWD and RWE and how it is being used currently. To enable them to express candid views, our experts have chosen to remain anonymous.A Vice President with expertise in HEOR at a top 10 global pharmaceutical company. A global market access and health economics executive previously employed at a top 30 global pharmaceutical company. A Real Life Evidence Manager at a top 20 global pharmaceutical company. A Vice President and Worldwide Head of Real World Evidence at a top 10 global pharmaceutical company. A Senior Director for Health Economics and Outcomes Research (HEOR) and Real World Evidence at a top 20 global pharmaceutical company. A Senior Director at a top 20 global pharmaceutical company. An Associate Director working for Global Health Economics and Outcomes Research (HEOR) at a top 10 global pharmaceutical company.
3 Key Quotes
“This is really a paradigm shift. In the past, global pharmaceutical companies could define which data is generated in global trials and then follow up post-market. We had a lot of control over which kinds of studies are running and what kind of data is being generated. In the new world, using real world data, this is changing. The majority of the data is not produced by pharma companies, it’s from healthcare systems, patients using devices, patients discussing products on social media, payers collecting data to process their transactions. This is the new world.”
“Secondary data sources like registries, claims databases, social media, apps and devices and electronic medical records are the data sources I would consider exciting and providing new opportunities.”
“The patient journey is the one of the most interesting areas for RWD. [It] will allow us to be even more specific to what patients need in the future…for me, this is one of the most exciting areas.”
Who Would Benefit from This Report?
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Real World Data (RWD) and Real World Evidence (RWE) are gaining traction across the industry. The front runners are already exploring new ways to collect and use data within their market access strategies and, for some, this is proving an effective way to ‘tip the balance’ from a no to a yes with target agencies. How well is pharma leveraging the data advantage? And how should companies benchmark their own RWD activities against the best of the rest?
Report Overview
Seven senior pharmaceutical company decision-makers currently working in Real World Data and Real World Evidence were all interviewed in depth. RWD Benchmarking Capabilities details their perspectives on the use of RWD and RWE for market access now and in the future, including opinions on who is leading the field and why.
Report Features
- Overview of the definitions and types of Real World Data, who is generating it, how it is being used successfully and the challenges being overcome.
- How Real World Data and Real World Evidence can improve performance within patient-centric strategies and outcomes-based contracts.
- The key issues regarding the effective use of Real World Data for market access including core requirements and limitations.
- Assessment of market activity including company profiles of the current Real World Data ‘movers and shakers’ as well as case studies and who to watch.
- New ideas on how to benchmark Real World Data activities, effective planning and analysis, and future trends to prepare for.
- Assess how your current data strategy stacks up: How do your Real World Data activities compare to other pharmaceutical companies? What do the data leaders have in common? How can you benchmark your market access data strategy?
- Understand more about the opportunities and threats: Just how important is social media? Which data sources are others already mining? What concerns exist regarding data quality, cost, and patient protection?
- Invigorate your strategy with new ideas and approaches: Avoid being overwhelmed by the enormity of the data task and gain greater clarity on the specific strategies and actions that have the most impact.
- Shape your long-term plans and data investments: Gain the insight and evidence needed to build a business plan to evolve and enhance your Real World Data strategy.
At the heart of the Real World Data revolution is the issue of control. Pharma companies used to be in the driving seat when it came to the data produced from trials and studies of their drugs. But now the floodgates have opened and everyone from payers to patients to your competitors can all see and comment on real world drug performance. And they are, in droves. This new data-rich environment presents significant opportunities but also threats. The key to success is finding a strategy that is sustainable, meets commercial objectives, and produces insight that is ultimately trusted enough to influence opinion.
Key Questions Answered By This Report
- Can RWD and RWE deliver results as stand-alone strategies or should they be coupled with price changes too?
- What practical steps can be taken to increase acceptance of RWD and RWE amongst HTA agencies and payers?
- How intrinsically linked is RWD and patient-centricity? Can it also be used to deliver against other core pharma business goals and if so, which ones?
- With seemingly limitless data sources available, what can be done to ensure disparate data are linked and subsequent analysis is robust, relevant and result-oriented?
- How will Real World Data evolve? Is collaboration the latest fad or should pharma be actively seeking new relationships? Which companies are the ones to watch?
Each of our experts have detailed understanding of RWD and RWE and how it is being used currently. To enable them to express candid views, our experts have chosen to remain anonymous.
3 Key Quotes
“This is really a paradigm shift. In the past, global pharmaceutical companies could define which data is generated in global trials and then follow up post-market. We had a lot of control over which kinds of studies are running and what kind of data is being generated. In the new world, using real world data, this is changing. The majority of the data is not produced by pharma companies, it’s from healthcare systems, patients using devices, patients discussing products on social media, payers collecting data to process their transactions. This is the new world.”
“Secondary data sources like registries, claims databases, social media, apps and devices and electronic medical records are the data sources I would consider exciting and providing new opportunities.”
“The patient journey is the one of the most interesting areas for RWD. [It] will allow us to be even more specific to what patients need in the future…for me, this is one of the most exciting areas.”
Who Would Benefit from This Report?
- Market access teams looking for new ways to boost the effectiveness of their RWD activity
- Patient liaison specialists investigating new sources of data and patient interaction methods
- Senior management planning for ongoing RWD investment, technology and resources
- Health economics and outcomes research (HEOR) professionals looking for new ways to boost coverage strategies
- Brand marketers concerned about competitor activity and the impact of data on market dynamics
- Payer liaison departments under increasing pressure to produce Real World Evidence
- Executive summary
- Research objectives and methodology
- Defining Real World Data and Real World Evidence
- Key findings
- Defining Real World Data
- Types of Real World Data
- Patient-centricity
- Diversity in Real World Data
- Growth in Real World Data availability
- Enablers for Real World Data
- Challenges for Real World Data
- Real World Data and Real World Evidence being generated by those outside of industry
- Real World Data and Real World Evidence for Market Access
- Key findings
- Intensifying interest in Real World Data and Real World Evidence
- Desire for Real World Value
- Real World Data can help overcome limitations in the evidence base
- Real World Data as the ’new normal’ for bringing a new product to market
- Real World Data and Real World Evidence are core requirements for outcomes-based contracts
- Real World Data and Real World Evidence is useful across the business
- Real World Data and Real World Evidence is relevant for all external stakeholders
- Companies that are leading on Real World Data
- Key findings
- Variability across companies
- The companies doing the most real world studies
- 2016 winner of the first Prix Galien Award for Real World Evidence
- Company profiles on Real World Data and Real World Evidence
- Key findings
- The companies with the most real world studies
- Pfizer
- AstraZeneca
- Bristol-Myers Squibb
- GlaxoSmithKline
- Bayer
- Hoffman-La Roche
- Other companies to watch
- Amgen
- Astellas
- Merck
- Novartis
- Novo Nordisk
- Sanofi
- Shire/Baxalta
- Commonalities across companies
- What can companies benchmark themselves on?
- Key findings
- Insights from within companies
- Planning: start early taking into account context
- Data and analysis: no single approach dominates
- Capability: More to do
- Plans for the future: Increasing investment in Real World Data and Real World Evidence
- Benchmarking
- Real World Data and collaboration
- Key findings
- The need to work together
- The future for RWD
- Key findings
- Real World Data and Real World Evidence will only get more important in the future
- Industry won’t be the only influencers of Real World Data and Real World Evidence
- Real World Data and Real World Evidence will become increasingly patient-centric
- Real World Data and Real World Evidence will underpin greater use of outcomes—based contracting
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. EXECUTIVE SUMMARY
2. RESEARCH OBJECTIVES AND METHODOLOGY
3. DEFINING REAL WORLD DATA AND REAL WORLD EVIDENCE
3.1 Key findings
3.2 Defining Real World Data
3.3 Types of Real World Data
3.4 Patient-centricity
3.5 Diversity in Real World Data
3.6 Enablers for Real World Data
3.7 Challenges for Real World Data
3.8 Real World Data and Real World Evidence are being generated by those outside of industry
4. REAL WORLD DATA AND REAL WORLD EVIDENCE FOR MARKET ACCESS
4.1 Key findings
4.2 Intensifying interest in Real World Data and Real World Evidence
4.3 Desire for Real World Value
4.4 Real World Data can help overcome limitations in the evidence base
4.5 Real World Data becoming the ’new normal’ for bringing a new product to market
4.6 Real World Data and Real World Evidence are core requirements for outcomes-based contracts
4.7 Real World Data and Real World Evidence is useful across the business
5. COMPANIES THAT ARE LEADING ON REAL WORLD DATA
5.1 Key findings
5.2 Variability across companies
5.3 The companies doing the most real world studies
5.4 Companies recognised for efforts to develop real world data
6. COMPANY PROFILES ON REAL WORLD DATA AND REAL WORLD EVIDENCE
6.1 Key findings
6.2 The companies with the most real world studies
6.2.1 Pfizer
6.2.2 AstraZeneca
6.2.3 Boehringer Ingelheim
6.2.4 Bristol-Myers Squibb
6.2.5 GlaxoSmithKline
6.2.6 Bayer
6.2.7 Hoffman-La Roche
6.3 Other companies to watch
6.3.1 Amgen
6.3.2 Astellas
6.3.3 Merck
6.3.4 Novartis
6.3.5 Novo Nordisk
6.3.6 Sanofi
6.3.7 Shire/Baxalta
6.4 Commonalities across companies
7. WHAT CAN COMPANIES BENCHMARK THEMSELVES ON?
7.1 Key findings
7.2 Insights from within companies
7.2.1 Planning: start early taking into account context
7.2.2 Data and analysis: no single approach dominates
7.2.3 Companies are still building Real World Data and Real World Evidence capabilities
8. REAL WORLD DATA AND COLLABORATION
8.1 Key findings
8.2 The need to work together
9. THE FUTURE FOR RWD
9.1 Key findings
9.2 Real World Data and Real World Evidence will only get more important in the future
9.3 Industry won’t be the only influencers of Real World Data and Real World Evidence
9.4 Real World Data and Real World Evidence will become increasingly patient-centric
9.5 Real World Data and Real World Evidence will underpin greater use of outcomes—based contracting
2. RESEARCH OBJECTIVES AND METHODOLOGY
3. DEFINING REAL WORLD DATA AND REAL WORLD EVIDENCE
3.1 Key findings
3.2 Defining Real World Data
3.3 Types of Real World Data
3.4 Patient-centricity
3.5 Diversity in Real World Data
3.6 Enablers for Real World Data
3.7 Challenges for Real World Data
3.8 Real World Data and Real World Evidence are being generated by those outside of industry
4. REAL WORLD DATA AND REAL WORLD EVIDENCE FOR MARKET ACCESS
4.1 Key findings
4.2 Intensifying interest in Real World Data and Real World Evidence
4.3 Desire for Real World Value
4.4 Real World Data can help overcome limitations in the evidence base
4.5 Real World Data becoming the ’new normal’ for bringing a new product to market
4.6 Real World Data and Real World Evidence are core requirements for outcomes-based contracts
4.7 Real World Data and Real World Evidence is useful across the business
5. COMPANIES THAT ARE LEADING ON REAL WORLD DATA
5.1 Key findings
5.2 Variability across companies
5.3 The companies doing the most real world studies
5.4 Companies recognised for efforts to develop real world data
6. COMPANY PROFILES ON REAL WORLD DATA AND REAL WORLD EVIDENCE
6.1 Key findings
6.2 The companies with the most real world studies
6.2.1 Pfizer
6.2.2 AstraZeneca
6.2.3 Boehringer Ingelheim
6.2.4 Bristol-Myers Squibb
6.2.5 GlaxoSmithKline
6.2.6 Bayer
6.2.7 Hoffman-La Roche
6.3 Other companies to watch
6.3.1 Amgen
6.3.2 Astellas
6.3.3 Merck
6.3.4 Novartis
6.3.5 Novo Nordisk
6.3.6 Sanofi
6.3.7 Shire/Baxalta
6.4 Commonalities across companies
7. WHAT CAN COMPANIES BENCHMARK THEMSELVES ON?
7.1 Key findings
7.2 Insights from within companies
7.2.1 Planning: start early taking into account context
7.2.2 Data and analysis: no single approach dominates
7.2.3 Companies are still building Real World Data and Real World Evidence capabilities
8. REAL WORLD DATA AND COLLABORATION
8.1 Key findings
8.2 The need to work together
9. THE FUTURE FOR RWD
9.1 Key findings
9.2 Real World Data and Real World Evidence will only get more important in the future
9.3 Industry won’t be the only influencers of Real World Data and Real World Evidence
9.4 Real World Data and Real World Evidence will become increasingly patient-centric
9.5 Real World Data and Real World Evidence will underpin greater use of outcomes—based contracting
